GOSS
Another day, another lawsuit
Gossamer Bio is back in the legal hot seat. Robbins LLP says a class action has been filed on behalf of investors who bought GOSS between June 16, 2025 and February 20, 2026, and the firm is now recruiting a lead plaintiff for the case.
The awkward part: PROSERA
The allegations center on whether Gossamer was too rosy about the viability of its PROSERA study. According to the notice, the company later blamed the miss on patients at Latin American sites doing unusually well on placebo, thanks to a heavily treated, lower-risk population. Translation: the story investors thought they were buying may not have matched the science on the ground.
Why investors care
The market already answered with a hard left turn. The notice says Gossamer’s stock fell from $2.13 on February 20, 2026 to $0.42 by February 23, 2025 — though that date appears to be a typo in the release. Either way, the point is clear: when biotech trial narratives wobble, the stock usually doesn’t just stumble, it faceplants.
Big picture
This is less about one lawsuit letter and more about the familiar biotech formula: clinical hope, investor expectations, then a nasty reality check. If the allegations hold up, Gossamer could be staring at a longer legal overhang — and for a small-cap biotech, that’s the financial equivalent of carrying a backpack full of bricks.